Anti-factor Xa assay versus aPTT for the monitoring of unfractionated heparin infusions in patients treated for cardiac indications

被引：0
|
作者：
Marston, Matthew, Jr. [1 ]
Heath, Emily [1 ]
Ford, Renee [1 ]
Griffin, Lukas [1 ]
Boudreau, Marybeth [1 ]
机构：
[1] Eastern Maine Med Ctr, Bangor, ME USA
来源：
PHARMACOTHERAPY | 2013年 / 33卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
29
引用
收藏
页码：E190 / E191
页数：2
相关论文
共 50 条
  • [1] SAFETY OF MONITORING UNFRACTIONATED HEPARIN INFUSIONS IN CRITICALLY ILL PATIENTS: ANTI-FACTOR XA VERSUS ACTIVATED PARTIAL THROMBOPLASTIN TIME (APTT)
    Burka, Abigail
    Cunningham, Michael
    Ernst, Neil
    Droege, Chris
    Hillebrand, Kristen
    Clark, Lindsey
    Tsuei, Betty
    Mueller, Eric
    [J]. CRITICAL CARE MEDICINE, 2012, 40 (12) : U279 - U279
  • [2] IS ANTI-FACTOR XA MONITORING BETTER THAN ACTIVATED PARTIALTHROMBOPLASTIN TIME (APTT) IN ACHIEVING THERAPEUTIC RESPONSE TO UNFRACTIONATED HEPARIN?
    Manzanades, Yuri
    [J]. NURSING IN CRITICAL CARE, 2021, 26 : 30 - 31
  • [3] Anti-factor Xa vs aPTT for heparin monitoring in extracorporeal membrane oxygenation
    Vo, Tai
    Bello, Abdel
    Ragan, Monika
    Flanagan, James
    Johnson, Darriel
    [J]. AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2023, 80 : S77 - S83
  • [4] Effects of four commercially available factor Xa proteins on the fluorogenic anti-factor Xa assay when monitoring unfractionated heparin
    Castro-Lopez, Vanessa
    Murray, Brian
    Harris, Leanne F.
    O'Donnell, James S.
    Killard, Anthony J.
    [J]. BLOOD COAGULATION & FIBRINOLYSIS, 2012, 23 (01) : 98 - 103
  • [5] IMPACT OF TARGETED TEMPERATURE MANAGEMENT ON ANTI-FACTOR XA MONITORING OF UNFRACTIONATED HEPARIN
    Fedkiv, Volodymyra
    Oh, Song
    Bingham, Angela
    Delic, Justin
    Igneri, Lauren
    Hollands, James
    [J]. CRITICAL CARE MEDICINE, 2021, 49 (01) : 596 - 596
  • [6] Automated anti-factor IIa assay for monitoring unfractionated heparin (UFH)
    Summerhayes, R.
    Ignjatovic, V
    Newall, F.
    Monagle, P.
    [J]. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2009, 7 : 1091 - 1091
  • [7] Comparing Anti-Factor Xa and Activated Partial Thromboplastin Levels for Monitoring Unfractionated Heparin
    Wahking, Rebekah A.
    Hargreaves, Rachel H.
    Lockwood, Sean M.
    Haskell, Sabrina K.
    Davis, Kelly W.
    [J]. ANNALS OF PHARMACOTHERAPY, 2019, 53 (08) : 801 - 805
  • [8] Lot-to-lot variation of unfractionated heparin using the anti-factor Xa assay.
    Pullen, GE
    Siegel, JE
    Goodell, LA
    [J]. AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2002, 118 (04) : 648 - 649
  • [9] POPULATION PHARMACOKINETIC AND PHARMACODYNAMIC MODELING OF UNFRACTIONATED HEPARIN USING ANTI-FACTOR XA ASSAY IN PEDIATRIC PATIENTS.
    Niu, T.
    Li, C.
    Ivaturi, V.
    Moffett, B.
    Gopalakrishnan, M.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2020, 107 : S94 - S94
  • [10] Anti-Factor Xa-Based Monitoring of Unfractionated Heparin: Clinical Outcomes in a Pediatric Cohort
    Saini, Surbhi
    Folta, Ashley N.
    Harsh, Katherine L.
    Stanek, Joseph R.
    Dunn, Amy L.
    O'Brien, Sarah H.
    Kumar, Riten
    [J]. JOURNAL OF PEDIATRICS, 2019, 209 : 212 - +
12345